GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Allogene Therapeutics Inc (NAS:ALLO) » Definitions » 12-1 Month Momentum %

Allogene Therapeutics (Allogene Therapeutics) 12-1 Month Momentum % : -17.68% (As of Apr. 30, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Allogene Therapeutics 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-30), Allogene Therapeutics's 12-1 Month Momentum % is -17.68%.

The industry rank for Allogene Therapeutics's 12-1 Month Momentum % or its related term are showing as below:

ALLO's 12-1 Month Momentum % is ranked better than
52.03% of 1478 companies
in the Biotechnology industry
Industry Median: -20.535 vs ALLO: -17.68

Competitive Comparison of Allogene Therapeutics's 12-1 Month Momentum %

For the Biotechnology subindustry, Allogene Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allogene Therapeutics's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Allogene Therapeutics's 12-1 Month Momentum % falls into.



Allogene Therapeutics  (NAS:ALLO) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %=( Price 1-month ago / Price 12-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allogene Therapeutics  (NAS:ALLO) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Allogene Therapeutics 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Allogene Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Allogene Therapeutics (Allogene Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
210 East Grand Avenue, South San Francisco, CA, USA, 94080
Allogene Therapeutics Inc is a United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.
Executives
Deborah M. Messemer director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Geoffrey M. Parker officer: CHIEF FINANCIAL OFFICER 15 RIORDAN PLACE, MENLO PARK CA 94025
Earl Martin Douglas officer: GENERAL COUNSEL BIOMIMETIC THERAPEUTICS, INC., 389 NICHOL MILL LANE, FRANKLIN TN 37067
Yinlin Jack Chen officer: SVP, Finance 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Timothy L. Moore officer: Chief Technical Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Lillian Smith officer: VP, Corporate Counsel 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Veer Bhavnagri officer: General Counsel C/O ALLOGENE THERAPEUTICS, INC., 210 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Zachary Roberts officer: EVP of R&D C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Owen N. Witte director C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rafael Amado officer: EVP of R&D and CMO 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Alison Moore officer: Chief Technical Officer C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Eric Thomas Schmidt officer: Chief Financial Officer C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
David D Chang director, officer: President and CEO C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004

Allogene Therapeutics (Allogene Therapeutics) Headlines